Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

May 01, 2006; Volume 34,Issue 5

Short Communications

  • You have access
    AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT
    Natalie L. Trevaskis, Christopher J.H. Porter and William N. Charman
    Drug Metabolism and Disposition May 2006, 34 (5) 729-733; DOI: https://doi.org/10.1124/dmd.105.008102
  • You have access
    HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
    J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
    Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

Articles

  • You have access
    ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN
    Liyue Huang, Yi Wang and Scott Grimm
    Drug Metabolism and Disposition May 2006, 34 (5) 738-742; DOI: https://doi.org/10.1124/dmd.105.007534
  • You have access
    INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID
    Harunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi Sugiyama
    Drug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375
  • You have access
    N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
    Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
    Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
  • You have access
    RIFAMPICIN INDUCTION OF CYP3A4 REQUIRES PREGNANE X RECEPTOR CROSS TALK WITH HEPATOCYTE NUCLEAR FACTOR 4α AND COACTIVATORS, AND SUPPRESSION OF SMALL HETERODIMER PARTNER GENE EXPRESSION
    Tiangang Li and John Y. L. Chiang
    Drug Metabolism and Disposition May 2006, 34 (5) 756-764; DOI: https://doi.org/10.1124/dmd.105.007575
  • You have access
    PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
    Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
    Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
  • You have access
    INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
    Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
    Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
  • You have access
    DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM
    Joseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. Bertino
    Drug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831
  • You have access
    IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES
    Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. Polli
    Drug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615
  • You have access
    EFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATE
    Rikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi Tamai
    Drug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559
  • You have access
    THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR
    Daisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi Sawada
    Drug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722
  • You have access
    BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES
    Wenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith Humphreys
    Drug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856
  • You have access
    OXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450
    Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu Chen
    Drug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849
  • You have access
    DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS
    Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi Yamazoe
    Drug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623
  • You have access
    EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
    Yang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. Thummel
    Drug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680
  • You have access
    THE ROLE OF CYP2A AND CYP2E1 IN THE METABOLISM OF 3-METHYLINDOLE IN PRIMARY CULTURED PORCINE HEPATOCYTES
    Michael A. Terner, W. James Gilmore, Yanping Lou and E. James Squires
    Drug Metabolism and Disposition May 2006, 34 (5) 848-854; DOI: https://doi.org/10.1124/dmd.105.008128
  • You have access
    EVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATION
    Stacey Becker and Xingrong Liu
    Drug Metabolism and Disposition May 2006, 34 (5) 855-861; DOI: https://doi.org/10.1124/dmd.105.007914
  • You have access
    OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER
    Rie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko Ikeda
    Drug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888
  • You have access
    GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING
    Lysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. Waring
    Drug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708
  • You have access
    THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
    Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. Zeldin
    Drug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672
  • You have access
    RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708
    John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. Dawson
    Drug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition: 34 (5)
Drug Metabolism and Disposition
Vol. 34, Issue 5
1 May 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Short Communications
  • Articles
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics